Jevtana (cabazitaxel)
- Region
- 🇪🇺 EU
- Active substance
- cabazitaxel
- Company
- Sanofi Winthrop Industrie
- Status
- Authorised
- Therapeutic area
- Prostatic Neoplasms
- CHMP opinion
- Thu 20 Jan 2011
- EU approval
- Thu 17 Mar 2011
- Application
- EMEA/H/C/002018
- ATC
- L01CD
- Official record
- www.ema.europa.eu
Indication
Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Cabazitaxel Accord Authorised · Accord Healthcare S.L.U.
- 🇪🇺 Cabazitaxel Teva Refused · Teva B.V.
Follow Jevtana
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.